Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;43(3):770-5.
doi: 10.1161/STROKEAHA.111.625574. Epub 2012 Jan 5.

The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study

Affiliations

The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study

Andrew D Barreto et al. Stroke. 2012 Mar.

Abstract

Background and purpose: Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPA plus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion.

Methods: During standard-dose intravenous tPA, a 100-μg/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75× baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography.

Results: Sixty-five patients were enrolled (45% men, mean age 63±14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target anticoagulation was reached at a median (interquartile range) of 3 (2-7) hours. Significant intracerebral hemorrhage occurred in 4 patients (6.2%; 95% CI, 1.7-15.0). Of these, 3 were symptomatic (4.6%; 95% CI, 0.9-12.9). Seven patients (10%) died in the first 7 days. Within the 2-hour monitoring period, transcranial Doppler recanalization (n=47) occurred in 29 (61%) patients: complete in 19 (40%) and partial in another 10 (21%).

Conclusions: The combination of Argatroban and intravenous tPA is potentially safe in patients with moderate neurological deficits due to proximal intracranial arterial occlusions and may produce more complete recanalization than tPA alone. Continued evaluation of this treatment combination is warranted.

Clinical trial registration: URL: www.clinicaltrials.gov. Unique identifier: NCT00268762.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Figures

Figure 1
Figure 1
PTT values: baseline (pre-tPA), 2, 6, 12, 24 and 48 hours. Target aPTT is displayed as the horizontal bar.

Comment in

References

    1. Walenga JM. An overview of the direct thrombin inhibitor argatroban. Pathophysiol Haemost Thromb. 2002;32 (Suppl 3):9–14. - PubMed
    1. Tanaka KA, Szlam F, Katori N, Sato N, Vega JD, Levy JH. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg. 2004;99:1283–1289. - PubMed
    1. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tpa) in acute myocardial infarction: Myocardial infarction with novastan and tpa (MINT) study. J Am Coll Cardiol. 1999;33:1879–1885. - PubMed
    1. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of argatroban. J Thromb Thrombolysis. 2001;12:141–149. - PubMed
    1. Wykrzykowska JJ, Kathiresan S, Jang IK. Clinician update: Direct thrombin inhibitors in acute coronary syndromes. J Thromb Thrombolysis. 2003;15:47–57. - PubMed

Publication types

MeSH terms

Associated data